GBP510
GBP510| 백신설명 | |
|---|---|
| 대상 | 사스-코브-2 |
| 백신종류 | 단백질 서브 유닛 |
| 임상자료 | |
| 경로: 행정 | 근육내 |
| 다음 시리즈의 일부 |
| COVID-19 전염병 |
|---|
 |
|
.svg){kind=small} COVID-19 포털 |
GBP510은 SK바이오사이언스와 GSK가 개발한 COVID-19 백신 후보물질이다.[1][2][3][4][5]
원래는 워싱턴 대학교 단백질 디자인 연구소에서 개발했다.[6][7]
임상 3상에는 4,037명이 참여한다.이번 재판으로 GBP510의 효능과 안전성이 확인될 경우 2022년 상반기 중 백신이 승인될 전망이다.[8][9][10][11]
부스터 선량 실험이 계획되고 있다.부스터는 2차 투여 후 6개월 후에 투여된다.[11]
참조
- ^ "SK COVID-19 Vaccine "GBP510" CEPI "Wave2" (next-generation vaccine)ed as the first development support target". SK Bioscience. 10 December 2020. Retrieved 28 July 2021.
- ^ "CEPI and SK bioscience extend collaboration to develop 'next generation' COVID-19 vaccine". Coalition for Epidemic Preparedness Innovations. 9 December 2020. Retrieved 28 July 2021.
- ^ "Safety and Immunogenicity Study of SARS-CoV-2 Nanoparticle Vaccine (GBP510) Adjuvanted With or Without AS03 (COVID-19)". ClinicalTrials.gov. 11 February 2021. NCT04750343. Retrieved 22 April 2021.
- ^ "Safety and Immunogenicity Study of SARS-CoV-2 Nanoparticle Vaccine (GBP510) Adjuvanted With Aluminum Hydroxide (COVID-19)". ClinicalTrials.gov. 8 February 2021. NCT04742738. Retrieved 22 April 2021.
- ^ Moon-hee C (11 June 2021). "SK Bioscience's COVID-19 Vaccine Uses Nanoparticle Technology of University of Washington". Business Korea. Retrieved 28 July 2021.
- ^ "Two nanoparticle vaccines enter clinical trials – Institute for Protein Design". Retrieved 18 August 2021.
- ^ "CEPI funds Phase 3 trial of UW Medicine COVID-19 vaccine". 24 May 2021.
- ^ "SK Bioscience advances first South Korean-developed COVID-19 vaccine to late-stage testing".
- ^ "SK Bioscience Starts to Administer COVID-19 Vaccines to Subjects in Phase 3 Trial". 31 August 2021.
- ^ SK Bioscience Co., Ltd. (14 October 2021). "A Phase III, Randomized, Active-controlled, Observer-blind, Parallel-group, Multi-center Study to Assess the Immunogenicity and Safety of SK SARS-CoV-2 Recombinant Nanoparticle Vaccine Adjuvanted With AS03 (GBP510) in Adults Aged 18 Years and Older". International Vaccine Institute, GlaxoSmithKline, Coalition for Epidemic Preparedness Innovations.
{{cite journal}}:Cite 저널은 필요로 한다.journal=(도움말) - ^ a b "IVI and SK bioscience Complete Recruitment for Phase III Clinical Trial of SKBS' COVID-19 Vaccine". Retrieved 7 February 2022.
 | 스콜리아는 GBP510 (Q108044254)에 대한 프로필을 가지고 있다. |
.png){kind=small}
